Suliana ManleyFrom 2016 Associate professor, EPFL, Lausanne, Switzerland
2009-2016 Tenure-track assistant professor, EPFL, Lausanne, Switzerland
2006-2009 Post-Doctoral fellow, National Institutes of Health, Bethesda, MD, USA
2004-2006 Post-Doctoral fellow, Massachusetts Institute of Technology, Cambridge, MA, USA
1999-2004 PhD (Physics) Awarded 06/2004, Harvard University, Cambridge, MA, USA
1993-1997 Bachelors (Cum Laude) Physics & Mathematics, Rice University, Houston, TX, USA
Chiara GabellaTeaching & PhD Courses Hands-on with Research Data Management in Chemistry ChE-601 PhD students in Chemistry will learn hands-on Research Data Management (RDM) skills transferable to their research practices. They willcontextualize their research into RDM best practices (day 1), discover appropriate tools (day 2) and work on a project (day 3) for the courseaccreditation
Andrea KrappTeaching & PhD Past EPFL PhD Students as codirector Claudia Melcarne Courses Practical - Karthaus Lab BIO-616 Students will learn 1) how organoids can be used in biomedical research 2) How to perform organoid culture 3) How to perform basic genetic manipulations
Coralie BussoExpériences professionnelles Apprentie Laborantine 2001–2004 CMU Dpt. de physiologie cellulaire et métabolisme
RechercheCentrosomes promote timely mitotic entry in C. ele Dev Cell. 2007 Apr;12(4):531-41.Centrosomes promote timely mitotic entry in C. elegans embryos.Hachet V, Canard C, Gönczy P.SourceSwiss Institute for Experimental Cancer Research (ISREC), and School of Life Sciences, Swiss Federal Institute of Technology (EPFL), CH-1066 Lausanne, Switzerland.AbstractSeveral mitotic regulators, including
Jürgen BruggerI am a Professor of Microengineering and co-affiliated to Materials Science. Before joining EPFL I was at the MESA Research Institute of Nanotechnology at the University of Twente in the Netherlands, at the IBM Zurich Research Laboratory, and at the Hitachi Central Research Laboratory, in Tokyo, Japan. I received a Master in Physical-Electronics and a PhD degree from Neuchâtel University, Switzerland. Research in my laboratory focuses on various aspects of MEMS and Nanotechnology. My group contributes to the field at the fundamental level as well as in technological development, as demonstrated by the start-ups that spun off from the lab. In our research, key competences are in micro/nanofabrication, additive micro-manufacturing, new materials for MEMS, increasingly for wearable and biomedical applications. Together with my students and colleagues we published over 200 peer-refereed papers and I had the pleasure to supervise over 25 PhD students. Former students and postdocs have been successful in receiving awards and starting their own scientific careers. I am honoured for the appointment in 2016 as Fellow of the IEEE “For contributions to micro and nano manufacturing technology”. In 2017 my lab was awarded an ERC AdvG in the field of advanced micro-manufacturing.
Aleksandra RadenovicFrom April 2021 Full Professor 2015 -2021 Associate Professor2008-2015 Tenure-Track Assistant Professor2004-2007 Postdoc at the University of California, Berkeley in the group of Prof.Liphardt2003 PhD student of Prof. Dietler in Laboratory of Physics of Living Matter, University of Lausanne 1999 Diploma thesis on the subject of the Raman spectroscopy of beta carotene1994-1999 Physics department at the University of Zagreb1994 baccalaureate, Classical gymnasium
Dominique PiolettiDominique Pioletti received his Master in Physics from the Swiss Federal Institute of Technology Lausanne (EPFL) in 1992. He pursued his education in the same Institution and obtained his PhD in biomechanics in 1997. He developed original constitutive laws taking into account viscoelasticity in large deformations. Then he spent two years at UCSD as post-doc fellow acquiring know-how in cell and molecular biology. He was interested in particular to gene expression of bone cells in contact to orthopedic implant. In April 2006, Dominique Pioletti was appointed Assistant Professor tenure-track at the EPFL and is director of the Laboratory of Biomechanical Orthopedics. His research topics include biomechanics and tissue engineering of musculo-skeletal tissues; mechano-transduction in bone; development of orthopedic implant as drug delivery system. Since 2013, he has been promoted to the rank of Associate Professor.
Bastien MangeatAddress
Bastien Mangeat, PhDGene Expression Core Facility (GECF)School of Life Sciences EPFL - Station 191015 LausanneSwitzerlandOffice: SV1535
Email for projects submissions and demands
Please use gecf@epfl.ch (one email per project)
Phone (email preferred)
Landline (only internal calls are answered): 37 113Mobile (important/urgent only): 41 79 752 20 86
Teaching & PhD Courses Methods: omics in biomedical research BIOENG-519 High-throughput methodologies broadly called Omics allow to charac Hervé LissekExpertise
Acoustics and audio engineering, Electroacoustics.Room acoustics.Active noise control.Acoustic metamaterials.Assisted reverberation.Psychoacoustics.Sound spatialization
Expertise
Acoustics and audio engineering, Electroacoustics.Room acoustics.Active noise control.Acoustic metamaterials.Assisted reverberation.Psychoacoustics.Sound spatialization
Mission
Head of the Acoustic Group at the Laboratory of Wave Engineering LWE. Research topics :Active Electroacoustic Resonators: turning conventional lou
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Graham KnottGraham Knott received his degree in physiology from the University of Southampton, UK, in 1990, and his PhD in neuroscience from the University of Tasmania, Australia, in 1995. He moved to the University of Lausanne in Switzerland in 1999 where he researched the plasticity of neuronal connectivity in the adult brain, developing correlative light and electron microscopy methods for the analysis of in vivo imaged neurons. In 2006 Graham joined the Ecole Polytechnique Fédérale de Lausanne, establishing the Bio Electron Microscopy Facility and has continued his research interests in brain plasticity and 3D electron microscopy.
Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Henry MarkramHenry Markram started a dual scientific and medical career at the University of Cape Town, in South Africa. His scientific work in the 80s revealed the polymodal receptive fields of pontomedullary reticular formation neurons in vivo and how acetylcholine re-organized these sensory maps.
He moved to Israel in 1988 and obtained his PhD at the Weizmann Institute where he discovered a link between acetylcholine and memory mechanisms by being the first to show that acetylcholine modulates the NMDA receptor in vitro studies, and thereby gates which synapses can undergo synaptic plasticity. He was also the first to characterize the electrical and anatomical properties of the cholinergic neurons in the medial septum diagonal band.
He carried out a first postdoctoral study as a Fulbright Scholar at the NIH, on the biophysics of ion channels on synaptic vesicles using sub-fractionation methods to isolate synaptic vesicles and patch-clamp recordings to characterize the ion channels. He carried out a second postdoctoral study at the Max Planck Institute, as a Minerva Fellow, where he discovered that individual action potentials propagating back into dendrites also cause pulsed influx of Ca2 into the dendrites and found that sub-threshold activity could also activated a low threshold Ca2 channel. He developed a model to show how different types of electrical activities can divert Ca2 to activate different intracellular targets depending on the speed of Ca2 influx an insight that helps explain how Ca2 acts as a universal second messenger. His most well known discovery is that of the millisecond watershed to judge the relevance of communication between neurons marked by the back-propagating action potential. This phenomenon is now called Spike Timing Dependent Plasticity (STDP), which many laboratories around the world have subsequently found in multiple brain regions and many theoreticians have incorporated as a learning rule. At the Max-Planck he also started exploring the micro-anatomical and physiological principles of the different neurons of the neocortex and of the mono-synaptic connections that they form - the first step towards a systematic reverse engineering of the neocortical microcircuitry to derive the blue prints of the cortical column in a manner that would allow computer model reconstruction.
He received a tenure track position at the Weizmann Institute where he continued the reverse engineering studies and also discovered a number of core principles of the structural and functional organization such as differential signaling onto different neurons, models of dynamic synapses with Misha Tsodyks, the computational functions of dynamic synapses, and how GABAergic neurons map onto interneurons and pyramidal neurons. A major contribution during this period was his discovery of Redistribution of Synaptic Efficacy (RSE), where he showed that co-activation of neurons does not only alter synaptic strength, but also the dynamics of transmission. At the Weizmann, he also found the tabula rasa principle which governs the random structural connectivity between pyramidal neurons and a non-random functional connectivity due to target selection. Markram also developed a novel computation framework with Wolfgang Maass to account for the impact of multiple time constants in neurons and synapses on information processing called liquid computing or high entropy computing.
In 2002, he was appointed Full professor at the EPFL where he founded and directed the Brain Mind Institute. During this time Markram continued his reverse engineering approaches and developed a series of new technologies to allow large-scale multi-neuron patch-clamp studies. Markrams lab discovered a novel microcircuit plasticity phenomenon where connections are formed and eliminated in a Darwinian manner as apposed to where synapses are strengthening or weakened as found for LTP. This was the first demonstration that neural circuits are constantly being re-wired and excitation can boost the rate of re-wiring.
At the EPFL he also completed the much of the reverse engineering studies on the neocortical microcircuitry, revealing deeper insight into the circuit design and built databases of the blue-print of the cortical column. In 2005 he used these databases to launched the Blue Brain Project. The BBP used IBMs most advanced supercomputers to reconstruct a detailed computer model of the neocortical column composed of 10000 neurons, more than 340 different types of neurons distributed according to a layer-based recipe of composition and interconnected with 30 million synapses (6 different types) according to synaptic mapping recipes. The Blue Brain team built dozens of applications that now allow automated reconstruction, simulation, visualization, analysis and calibration of detailed microcircuits. This Proof of Concept completed, Markrams lab has now set the agenda towards whole brain and molecular modeling.
With an in depth understanding of the neocortical microcircuit, Markram set a path to determine how the neocortex changes in Autism. He found hyper-reactivity due to hyper-connectivity in the circuitry and hyper-plasticity due to hyper-NMDA expression. Similar findings in the Amygdala together with behavioral evidence that the animal model of autism expressed hyper-fear led to the novel theory of Autism called the Intense World Syndrome proposed by Henry and Kamila Markram. The Intense World Syndrome claims that the brain of an Autist is hyper-sensitive and hyper-plastic which renders the world painfully intense and the brain overly autonomous. The theory is acquiring rapid recognition and many new studies have extended the findings to other brain regions and to other models of autism.
Markram aims to eventually build detailed computer models of brains of mammals to pioneer simulation-based research in the neuroscience which could serve to aggregate, integrate, unify and validate our knowledge of the brain and to use such a facility as a new tool to explore the emergence of intelligence and higher cognitive functions in the brain, and explore hypotheses of diseases as well as treatments.
